Aquatic Capital Management LLC Denali Therapeutics Inc. Transaction History

Aquatic Capital Management LLC

  • $3.8 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$16.2 - $23.18 $162,000 - $231,800
-10,000 Reduced 54.64%
8,300 $178,000
Q3 2023

Nov 14, 2023
BUY
$20.63 - $30.17 $336,269 - $491,771
16,300 Added 815.0%
18,300 $378,000
Q2 2023

Aug 14, 2023
SELL
$23.37 - $32.96 $42,066 - $59,328
-1,800 Reduced 47.37%
2,000 $59,000
Q1 2023

May 15, 2023
BUY
$21.91 - $32.67 $83,258 - $124,146
3,800 New
3,800 $88,000
Q2 2022

Aug 15, 2022
SELL
$20.88 - $35.19 $22,968 - $38,709
-1,100 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$29.0 - $47.27 $31,900 - $51,997
1,100 New
1,100 $35,000

Others Institutions Holding DNLI

# of Institutions
227
Shares Held
119M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Aquatic Capital Management LLC Portfolio

Follow Aquatic Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aquatic Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email